Oppenheimer Reiterates Opiant Pharma (OPNT) at Outperform Following Earnings
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $42.00 price target on Opiant Pharma (NASDAQ: OPNT), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
